Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2017–2040 of 5,931 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Mouth Disease Clear all

Conditions: Tumors Characterized by Genetic Abnormalities of ALK
Interventions: LDK378; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 6
States / cities: Aurora, Colorado • Boston, Massachusetts • New York, New York + 3 more

Conditions: Huntington's Disease
Interventions: Laquinimod, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 21 Years to 55 Years
Enrollment: 352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 16
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 13 more

Conditions: Xerostomia, Head and Neck Cancer
Interventions: Bone Marrow Aspiration, Ultrasound Imaging of Salivary Glands, Salivary Assay, Quality of Life Instruments; Procedure · Diagnostic Test · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 89 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Herpes Labialis
Interventions: acyclovir/hydrocortisone cream; Drug
Lead sponsor: Meda Pharmaceuticals; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 10
States / cities: Los Angeles, California • Opa-locka, Florida • West Palm Beach, Florida + 7 more

Conditions: Rubella, Measles, Mumps
Interventions: Priorix, M-M-R II, Varivax, Havrix, Prevnar 13; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Months to 15 Months
Enrollment: 5,016 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 62
States / cities: Dothan, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 56 more

Conditions: Anemia, Iron Deficiency, Delivery Complication
Interventions: Ferrous sulfate, Iron dextran; Drug
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Chronic Lymphocytic Leukemia (CLL)
Interventions: Venetoclax, Obinutuzumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 15
States / cities: La Jolla, California • Atlanta, Georgia • Des Moines, Iowa + 12 more

Conditions: Fibroid
Interventions: PRA-027; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 60 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Gingivitis, Plaque
Interventions: Oscillating-rotating electric toothbrush, Side-to-side electric toothbrush, Manual toothbrush; Device
Lead sponsor: Procter and Gamble; Industry
Eligibility: 18 Years and older
Enrollment: 2,145 participants
Timeline: 2018
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Palatal Neoplasms, Lip Neoplasm, Gingival Neoplasms, Leukoplakia, Oral, Tongue Neoplasms, Oropharyngeal Neoplasms, Oral Ulcer
Interventions: OncAlert; Device
Lead sponsor: Vigilant Biosciences, Inc.; Industry
Eligibility: 23 Years and older
Enrollment: 893 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 26
States / cities: Beverly Hills, California • La Mesa, California • Loma Linda, California + 22 more

Conditions: C. Difficile, Diarrhea, Enterocolitis
Interventions: Fidaxomicin, Metronidazole, Vancomycin; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Pre-diabetes
Interventions: vitamin D, placebo; Drug
Lead sponsor: Charles Drew University of Medicine and Science; Other
Eligibility: 18 Years to 90 Years
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Salivary Gland Cancer, Salivary Gland Adenoid Cystic Carcinoma, Stage III Adenoid Cystic Carcinoma of the Oral Cavity, Stage III Salivary Gland Cancer, Stage IV Adenoid Cystic Carcinoma of the Oral Cavity, Stage IV Salivary Gland Cancer
Interventions: bortezomib, doxorubicin hydrochloride, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Tobacco Use Disorder
Interventions: Camel Snus, Marlboro Snus, Stonewall, Ariva, General Snus; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 70 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Eugene, Oregon

Conditions: Restless Legs Syndrome, Ekbom Syndrome, Willis-Ekbom Disease
Interventions: Rotigotine; Drug
Lead sponsor: John Winkelman, MD, PhD; Other
Eligibility: 18 Years to 75 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Oral Mucositis
Interventions: AG013, Placebo; Biological · Other
Lead sponsor: Oragenics, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 27
States / cities: Farmington, Connecticut • Newark, Delaware • Orlando, Florida + 24 more

Conditions: Gastroparesis
Interventions: Gastric endoscopic peroral pyloromyotomy, Esophago-gastro-duodenoscopy; Procedure
Lead sponsor: Institute for Clinical and Experimental Medicine; Government
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Prevention of Thromboembolic Events, Atrial Fibrillation
Interventions: Apixaban; Drug
Lead sponsor: Bayer; Industry
Eligibility: 45 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Whippany, New Jersey

Conditions: Peanut Allergy
Interventions: INT301, Placebo; Drug
Lead sponsor: Intrommune Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Belleville, New Jersey • Riverdale, New Jersey

Conditions: Herpes Labialis
Interventions: valacyclovir+clobetasol gel; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Candidiasis, Esophageal, HIV Infections
Interventions: Itraconazole, Fluconazole; Drug
Lead sponsor: Janssen Pharmaceuticals; Industry
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 18
States / cities: Tucson, Arizona • Los Angeles, California • San Diego, California + 14 more

Conditions: Bladder Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: tanespimycin; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2005
U.S. locations: 2
States / cities: Los Angeles, California • New York, New York

Conditions: Respiratory Tract Infections
Interventions: PF-04287881, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Myocardial Infarction, Heart Failure, Heart Enlargement
Interventions: PG-116800 (given as PG-530742), Placebo tablet; Drug
Lead sponsor: Procter and Gamble; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 253 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 21
States / cities: Little Rock, Arkansas • Merced, California • Denver, Colorado + 18 more

Search by objective public record fields.

A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase

A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod

Salivary Gland Autotransplantation for Treatment of XRT Induced Xerostomia

Open Label Safety Study of Xerese Cream in the Treatment of Recurrent Herpes Labialis in Children 6-11 Years Old

Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age

Intravenous Iron vs. Oral Iron Supplementation for Postpartum Anemia

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

Study of the Safety, Tolerability, and PK of PRA-027 Administered to Women of Nonchildbearing Potential

The Effects of Oscillating-Rotating Electric Toothbrushes on Plaque and Gingival Health

Clinical Evaluation of the OncAlert RAPID in Subjects Presenting for Evaluation and/or Initial Biopsy; Impact on Decision-Making

Impact of Oral Antibiotic Treatment on C. Difficile

Vitamin D in Minorities With Prediabetes

Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck

Evaluation of Oral Tobacco as a Harm Reduction Method for Smokers

Switching From Oral Dopamine Agonists to Rotigotine

Efficacy, Safety and Tolerability of AG013 in Oral Mucositis Compared to Placebo When Administered Three Times Per Day

Endoscopic Pyloromyotomy for Refractory Gastroparesis

An Observational Study (Called RETAF-PS) Using a Patient Survey to Learn More About Treatment Outcomes in Patients With Irregular and Often Rapid Heartbeat (Atrial Fibrillation) Treated With Apixaban in a Real World Setting

OMEGA Study: A Study of the Safety and Feasibility of Up-titration With INT301 in Adults With Sensitivity to Peanut

Valacyclovir+Temovate Gel for the Treatment of Herpes Labialis

Randomized, Controlled, Double-Blind Study of Itraconazole Oral Solution Versus Fluconazole Tablets for the Treatment of Esophageal Candidiasis.

Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer

Safety And Pharmacokinetics Study Of PF-04287881 In Healthy Adults

Study of Oral PG-116800 Following a Heart Attack